Sunshine Biopharma Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing continued operating losses alongside growth in cash and total assets compared to December 31, 2025.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $4,031,857 for the nine months ended September 30, 2026, compared to a net loss of $3,834,425 for the same period in 2025.
  • Revenue: Nine-month revenue was $26,794,777, down from $27,728,750 in the nine months ended September 30, 2025.
  • Cash position: Cash and cash equivalents stood at $14,618,614 as of September 30, 2026, up from $9,123,308 at December 31, 2025.
  • Total assets: Total assets were $33,858,957 at September 30, 2026, compared to $30,079,167 at December 31, 2025.
  • Financing activity: The company raised net proceeds of $7,316,895 from a public offering of common stock and $2,719,185 from the exercise of warrants during the nine-month period.
  • Share count: Common shares issued and outstanding were 278,317 at September 30, 2026, rising from 24,530 at December 31, 2025; shares outstanding as of November 12, 2026 were reported as 823,772.
  • Accumulated deficit: The accumulated deficit reached $79,046,983 as of September 30, 2026, compared to $75,015,126 at December 31, 2025.

Sunshine Biopharma's Financial Results for the Quarter and Nine Months Ended September 30, 2026

According to the filing, Sunshine Biopharma Inc. (NASDAQ:SBFM) reported a net loss of $1,223,940 for the three months ended September 30, 2026, compared to a net loss of $883,820 for the same quarter in 2025. For the nine months ended September 30, 2026, the net loss was $4,031,857 versus $3,834,425 for the prior-year period. Revenue for the third quarter of 2026 was $9,442,325, nearly flat compared to $9,417,179 in the third quarter of 2025. Gross profit for the quarter was $3,101,702, up slightly from $3,073,540 in the year-ago quarter.

The filing disclosed that total general and administrative expenses for the nine months ended September 30, 2026 were $12,008,321, down from $13,663,850 in the same period of 2025, with the prior-year figure including $1,616,459 of intangible asset impairment charges not present in the current period. Salaries represented the largest G&A line item at $5,488,485 for the nine months ended September 30, 2026. The company reported a loss from operations of $4,298,947 for the nine-month period, compared to $4,437,018 in the same period of 2025.

On the balance sheet, the company reported total shareholders' equity of $28,637,238 at September 30, 2026, up from $23,038,460 at December 31, 2025. Total liabilities decreased to $5,221,719 from $7,040,707 over the same period. Net cash used in operating activities for the nine months was $4,374,080. The company's basic loss per common share for the nine months ended September 30, 2026 was $(26.43), compared to $(195.37) for the nine months ended September 30, 2025, reflecting the significantly higher weighted average share count of 152,539 versus 19,626 in the prior-year period.

What Was Disclosed

Sunshine Biopharma's 10-Q for the nine months ended September 30, 2026 reported a net loss of $4,031,857, nine-month revenue of $26,794,777, cash of $14,618,614, and total assets of $33,858,957, alongside a sharply higher common share count due to stock issuances and warrant exercises.